How the HEK to improve AAV manufacturability

High manufacturing costs, problematic payloads and low HEK cell production yields can all limit the potential of AAV-based gene therapies. In this webinar, we will explore two new technologies helping to unlock higher productivity and improve vector quality for more cost-effective process development.  

Join our panel of experts who will guide you through early performance data and discuss the impact of these novel technologies on viral vector manufacturing.  

You will learn about:  

• Key challenges associated with AAV production
• How to address production issues caused by challenging transgenes using the Vectonize™ transgene expression technology  
• How to dramatically increase the percentage of full capsids using the HEKcellence™ expression system
• How to join our beta testing program and become a most HEKellent beta tester!  

Speakers:

Tulshi Patel, Ph.D.
Global Field Application Scientist, Bioproduction, Revvity

Sebastian Fladerer, Ph.D.
Scientist Vector Development, Revvity

Irene Ferreira, Ph.D.
Strategy Leader, Viral Vector Manufacturing, Revvity

The Vectonize™ technology and HEKcellence™ platform are available for research, clinical, and commercialization applications, including services, under specific limited licenses from Revvity.